Insufficient scRNA-seq data for expression of APOBEC3H at single-cell level.
Insufficient scRNA-seq data for expression of APOBEC3H at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 81.57 | 576 / 578 | 86% | 3.67 | 995 / 1155 |
thymus | 94% | 35.11 | 611 / 653 | 92% | 4.57 | 556 / 605 |
uterus | 94% | 25.16 | 159 / 170 | 77% | 2.99 | 352 / 459 |
kidney | 81% | 24.94 | 72 / 89 | 79% | 3.52 | 709 / 901 |
bladder | 81% | 39.48 | 17 / 21 | 78% | 3.62 | 393 / 504 |
breast | 85% | 21.88 | 391 / 459 | 68% | 2.13 | 756 / 1118 |
stomach | 88% | 28.96 | 316 / 359 | 55% | 1.71 | 157 / 286 |
ovary | 77% | 16.24 | 138 / 180 | 62% | 1.69 | 267 / 430 |
skin | 55% | 8.70 | 996 / 1809 | 77% | 3.54 | 365 / 472 |
esophagus | 83% | 17.92 | 1206 / 1445 | 45% | 1.16 | 83 / 183 |
intestine | 85% | 29.09 | 821 / 966 | 42% | 1.11 | 221 / 527 |
prostate | 92% | 34.04 | 226 / 245 | 34% | 0.66 | 172 / 502 |
adrenal gland | 92% | 37.01 | 237 / 258 | 18% | 0.49 | 41 / 230 |
pancreas | 39% | 6.05 | 127 / 328 | 69% | 1.98 | 122 / 178 |
liver | 60% | 11.43 | 136 / 226 | 41% | 1.06 | 165 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 15.73 | 29 / 29 |
spleen | 100% | 140.72 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.26 | 1 / 1 |
peripheral blood | 99% | 268.03 | 916 / 929 | 0% | 0 | 0 / 0 |
brain | 55% | 10.49 | 1450 / 2642 | 38% | 0.75 | 267 / 705 |
tonsil | 0% | 0 | 0 / 0 | 89% | 5.16 | 40 / 45 |
adipose | 88% | 28.18 | 1059 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 85% | 25.41 | 1132 / 1335 | 0% | 0 | 0 / 0 |
heart | 56% | 9.83 | 482 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 54% | 1.42 | 43 / 80 |
muscle | 10% | 1.13 | 83 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0010526 | Biological process | retrotransposon silencing |
GO_0051607 | Biological process | defense response to virus |
GO_0045869 | Biological process | negative regulation of single stranded viral RNA replication via double stranded DNA intermediate |
GO_0016554 | Biological process | cytidine to uridine editing |
GO_0044355 | Biological process | clearance of foreign intracellular DNA |
GO_0044828 | Biological process | negative regulation by host of viral genome replication |
GO_0070383 | Biological process | DNA cytosine deamination |
GO_0009972 | Biological process | cytidine deamination |
GO_0045087 | Biological process | innate immune response |
GO_0000932 | Cellular component | P-body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004126 | Molecular function | cytidine deaminase activity |
GO_0003723 | Molecular function | RNA binding |
Gene name | APOBEC3H |
Protein name | DNA dC->dU-editing enzyme APOBEC-3H (EC 3.5.4.38) (APOBEC-related protein 10) (ARP-10) (Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3H) (A3H) single-stranded DNA cytosine deaminase (EC 3.5.4.38) |
Synonyms | |
Description | FUNCTION: DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. The A3H-var/haplotype 2 exhibits antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity also against T-cell leukemia virus type 1 (HTLV-1) and may inhibit the mobility of LTR and non-LTR retrotransposons. . |
Accessions | A0A087WZI3 B7TQM4 Q6NTF7 ENST00000613677.4 [Q6NTF7-1] B7TQM6 ENST00000348946.8 [Q6NTF7-2] B7T0V0 ENST00000401756.5 [Q6NTF7-1] B7TQM8 ENST00000613996.1 B7TQM9 ENST00000442487.8 [Q6NTF7-3] B7TQM3 B7TQM7 ENST00000421988.6 |